Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.
This ongoing study, called AtDvance, is for adults with moderate to severe atopic dermatitis, which is a common type of eczema. The main goal is to understand the long-term safety of a new medicine, GSK1070806. Researchers will carefully watch for any side effects and see how many people might need to stop the treatment because of them. They also want to see how well the medicine works over many weeks and months by checking improvements in eczema symptoms like redness, itching, and skin thickness. This is a Phase II study, meaning it's still in the earlier stages of drug development, exploring if the treatment is effective and safe enough to continue testing on more people.
At a glance
What is this study about?
This research study, known as AtDvance, is investigating a new medication called GSK1070806 for adults who have moderate to severe atopic dermatitis. Atopic dermatitis is a long-lasting skin condition that causes itchy, red, dry, and sometimes cracked skin. When the condition is moderate to severe, it can have a big impact on a person's daily life.
The main purpose of this study is to explore the long-term safety and effectiveness of this new medicine. Researchers will be carefully monitoring participants for any side effects that might occur, both common and more serious ones. They will also track how well the medicine helps to improve eczema symptoms over an extended period. This is important to understand if the treatment can offer lasting relief and be a good option for people living with this condition.
By taking part in studies like this, researchers hope to find better ways to manage atopic dermatitis. It's an important step in developing new treatments that could potentially improve the quality of life for many people. The information gathered will help doctors and scientists understand if GSK1070806 could be a safe and effective treatment option in the future.
Key takeaways
- This study is testing a new medicine (GSK1070806) for moderate to severe eczema.
- It's a long-term study focusing on safety and how well the medicine works over time.
- Participants must be adults (18+) with atopic dermatitis.
- The study aims to find better treatments for eczema patients.
- Your health and any side effects will be carefully monitored.
- You can stop participating at any time.
Who may be eligible?
This study is looking for adults who are 18 years old or older. There is no upper age limit, meaning older adults can also take part. Both men and women are welcome to join this research.
The most important criteria is that you must have moderate to severe atopic dermatitis (eczema). This means your eczema affects a noticeable part of your body and often causes significant symptoms like intense itching, redness, or skin thickening.
Since this is a follow-up study, potential participants would likely have already taken part in a previous study involving GSK1070806. The research team will review your medical history to make sure the study medication is suitable and safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of moderate to severe atopic dermatitis (eczema)?
- Have you previously participated in a study involving GSK1070806?
- Are you able to attend regular clinic visits for an extended period?
What does participation involve?
If you join this study, you will be given the study medication, GSK1070806, usually at regular intervals. You will have scheduled visits to the clinic over a long period. At these visits, doctors and nurses will check your overall health, carefully record any side effects you might experience, and assess how your eczema is improving. They will also take measurements and ask you questions about your symptoms, such as how itchy your skin is, and how your eczema affects your daily life. The study involves long-term follow-up; while specific total duration isn't given, 'every 48 weeks thereafter' suggests it could go on for several years. You'll receive routine care instructions and support throughout the study.
Potential risks and benefits
Locations (8)
- —UnverifiedCzechia
- —UnverifiedPoland
- —UnverifiedGermany
- —UnverifiedItaly
- —UnverifiedBulgaria
- —UnverifiedFrance
- —UnverifiedSpain
- —UnverifiedGreece
Common questions
What is atopic dermatitis (eczema)?
It's a common, long-lasting skin condition that makes your skin dry, red, itchy, and sometimes cracked or raw.
What does 'moderate to severe' eczema mean?
It means your eczema is affecting a significant part of your body, causing bothersome symptoms that often impact your daily life.
What is GSK1070806?
It's a new medicine being studied for moderate to severe atopic dermatitis, aiming to improve symptoms and overall skin health.
Why is this study called a 'long-term extension'?
This means it's a continuation of earlier studies, following participants for a longer time to understand the medicine's effects over many months or years.
Will I receive the new medicine?
Yes, if you meet all the study requirements and choose to participate, you will receive doses of GSK1070806 during the study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.